Diagnostic power of 24S-hydroxycholesterol in cerebrospinal fluid: Candidate marker of brain health

Journal of Alzheimer's Disease

Volumn 36, Issue 4, 2013, Pages 739-747

  Leoni, Valerio ^a   Solomon, Alina ^b,e,f   Lövgren Sandblom, Anita ^b   Minthon, Lennart ^c   Blennow, Kaj ^d   Hansson, Oskar ^c   Wahlund, Lars Olof ^b,e,f   Kivipelto, Miia ^b,e,f   Björkhem, Ingemar ^b  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e KAROLINSKA INSTITUTE   (Sweden)

^f UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Aging; ApoE; biomarker; cholesterol; cognitive decline; mass spectrometry; neurodegenerative diseases; oxysterols

Indexed keywords

24 HYDROXYCHOLESTEROL; CHOLESTEROL DERIVATIVE; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FOLLOW UP; HUMAN; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; BRAIN; FEMALE; HUMANS; HYDROXYCHOLESTEROLS; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT;

EID: 84881440031     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-130035     Document Type: Article

References (33)

1. Petersen RC, Roberts RO, Knopman DS, Boeve BF, Geda YE, Ivnik RJ, Smith GE, Jack CR Jr (2009) Mild cognitive impairment: Ten years later. Arch Neurol 66, 1447-1455.
2. BlennowK, ZetterbergH(2009) Cerebrospinal fluid biomarkers for Alzheimer's disease. J Alzheimer Dis 18, 413-417.
3. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rośen E, Aarsland D, Visser PJ, Schröder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttilä T, Wallin A, Jönhagen ME, Minthon L, Winblad B, Blennow K (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 22, 385-393.
4. Dean RA, Shaw LM (2010) Use of cerebrospinal fluid biomarkers for diagnosis of incipient Alzheimer's disease in patients with mild cognitive impairment. Clin Chem 56, 17-19.
5. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 56, 303-308.
6. Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO, Freund-Levi Y, Tsolaki M, Minthon L, Wallin AK, Hampel H, Bürger K, Pirttila T, Soininen H, Rikkert MO, Verbeek MM, Spiru L, Blennow K (2009) Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: A prospective cohort study. Lancet Neurol 8, 619-627.
7. Leoni V, Masterman T, Mousavi FS, Wretlind B, Wahlund LO, Diczfalusy U, Hillert J, Björkhem I (2004) Diagnostic use of cerebral and extracerebral oxysterols. Clin Chem Lab Med 42, 186-191.
8. Björkhem I (2006) Crossing the barrier. Oxysterols as cholesterol transporters and metabolic modulators in the brain. J Internal Med 260, 493-508.
9. Passotiropoulos A, Lutjohann D, Bagli M, Locatelli M, Jessen F, Buschfort R, Ptok U, Björkhem I, Heun R (2002) 24SHydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. J Psychiatr Res 36, 27-32.
10. Schonknecht P, Lutjohann D, Pantel J, Bardenheuer H, Hartmann T, von Bergmann K, Beyreuther K, Schröder J (2002) Cerebrospinal fluid 24S-hydroxycholesterol is increased in patients with Alzheimer's disease compared to healthy controls. Neurosci Lett 324, 83-85.
11. Leoni V, Shafaati M, Salomon A, Kivipelto M, Björkhem I, Wahlund LO (2006) Are the CSF levels of 24Shydroxycholesterol a sensitive biomarker for mild cognitive impairment?. Neurosci Lett 397, 83-87.
12. Shafaati M, Solomon A, Kivipelto M, Björkhem I, Leoni V (2007) Levels of ApoE in cerebrospinal fluid are correlated with T-tau and 24S-hydroxycholesterol in patients with cognitive disorders. Neurosci Lett 425, 78-82.
13. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944
14. Stomrud E, Forsberg A, Hägersröm D, Ryding E, Blennow K, Zetterberg H, Minthon L, Hansson O, Londos E (2012) CSF biomarkers correlate with cerebral blood flow on SPECT in healthy subjects. Dement Geriatr Cogn Disord 3, 156-163.
15. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, 4th ed. American Psychiatric Association, Washington, D.C.
16. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Bäckman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, de Leon M, DeCarli C, Erkinjuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, van Duijn C, Visser P, Petersen RC (2004) Mild cognitive impairment - beyond controversies, towards a consensus: Report of the International Working Group on Mild Cognitive Impairment. J Intern Med 256, 240-246.
17. Blennow K, Wallin A, Å gren H, Spenger C, Siegfried J, Vanmechelen E (1995) T-tau protein in cerebrospinal fluid: A biochemical diagnostic marker for axonal degeneration in Alzheimer's disease?. Mol Chem Neuropathol 26, 231-245.
18. Vanmechelen E, Vanderstichele H, Davidsson P, van Kerschaver E, van der Perre B, Sjögren M, Andreasen N, Blennow K (2000) Quantification of T-tau phosphorylated at threonine 181 in human cerebrospinal fluid: A sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 285, 49-52.
19. Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, Vanderstichele H, Vanmechelen E, Blennow K (1999) Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: Differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol 56, 673-680.
20. Leoni V, Caccia C (2012) 24S-hydroxycholesterol in plasma: A marker of cholesterol turnover in neurodegenerative diseases. Biochimie 95, 595-612.
21. Leoni V, Caccia C (2011) Oxysterols as biomarkers in neurodegenerative diseases. Chem Phys Lipids 164, 515-524.
22. Abildayeva K, Jansen PJ, Hirsch-Reinshagen V, Bloks VW, BakkerAH,Ramaekers FC, deVente J, GroenAK,Wellington CL, Kuipers F, Mulder M (2006) 24(S)-hydroxycholesterol participates in a liver X receptor-controlled pathway in astrocytes that regulates apolipoprotein E-mediated cholesterol efflux. J Biol Chem 281, 12799-12808.
23. Bu G (2009) Apolipoprotein E and its receptors in Alzheimer's disease: Pathways, pathogenesis and therapy. Nat Rev Neurosci 10, 333-344.
24. Shafaati M, Olin M, B̊avner A, Pettersson H, Rozell B, Meaney S, Parini P, Björkhem I (2011) Enhanced production of the endogenous LXR ligand 24S-hydroxycholesterol is not sufficient to drive LXR-dependent gene expression in vivo. J Internal Med 270, 377-387.
25. Quigely H, Colloby SJ, O'Brien JT (2011) PET imaging of brain amyloid in dementia: A review. Int J Geriatr Psychiatry 26, 991-999.
26. De Meyer G, Shapiro F, Vanderstichele H, Vanmechelen E, Engelborghs S, De Deyn PP, Coart E, Hansson O, Minthon L, Zetterberg H, Blennow K, Shaw L, Trojanowski JQ, Alzheimer's Disease Neuroimaging Initiative (2010) Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol 67, 949-956.
27. de Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, Rusinek H, Li J, TsuiW, Saint Louis LA, Clark CM, Tarshish C, Li Y, Lair L, Javier E, Rich K, Lesbre P, Mosconi L, Reisberg B, Sadowski M, DeBernadis JF, Kerkman DJ, Hampel H, Wahlund LO, Davies P (2006) Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging 27, 394-401.
28. Glodzik-Sobanska L, Pirraglia E, Brys M, de Santi S, Mosconi L, Rich KE, Switalski R, Saint Louis L, Sadowski MJ, Martiniuk F, Mehta P, Pratico D, Zinkowski RP, Blennow K, de Leon MJ (2009) The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease. Neurobiol Aging 30, 672-681.
29. Buchhave P, Blennow K, Zetterberg H, Stomrud E, Londos E, Andreasen N, Minthon L, Hansson O (2009) Longitudinal study of CSF biomarkers in patients with Alzheimer's disease. PLoS One 4, e6 294.
30. FaganAM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM (2007) Cerebrospinal fluid tau/beta-amyloid (42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 64, 343-349.
31. Snider BJ, Fagan AM, Roe C, Shah AR, Grant EA, Xiong C, Morris JC, Holtzman DM (2009) Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Arch Neurol 66, 638-645.
32. Li G, Sokal I, Quinn JF, Leverenz JB, BrodeyM, Schellenberg GD, Kaye JA, Raskind MA, Zhang J, Peskind ER, Montine TJ (2007) CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: A follow-up study. Neurology 69, 631-639.
33. Popp J, Lewczuk P, Frommann I, Kölsch H, Kornhuber J, Maier W, Jessen F (2010) Cerebrospinal fluid markers for Alzheimer's disease over the lifespan: Effects of age and the APOE-4 genotype. J Alzheimers Dis 22, 459-468.